NCT00024024View on ClinicalTrials.gov

BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

August 31, 2001

Primary Completion Date

August 31, 2003

Conditions
Sarcoma
Interventions
DRUG

rebimastat

Trial Locations (3)

10032

Herbert Irving Comprehensive Cancer Center, New York

63110

Washington University School of Medicine, St Louis

60611-3013

Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00024024 - BMS-275291 in Treating Patients With HIV-Related Kaposi's Sarcoma | Biotech Hunter | Biotech Hunter